MP
Adaptive Biotechnologies Pipeline
| Drug | Indication | Phase |
|---|---|---|
| clonoSEQ (MM, BM) | Multiple Myeloma | FDA-Cleared |
| clonoSEQ (ALL, BM) | Acute Lymphoblastic Leukemia | FDA-Cleared |
| clonoSEQ (CLL, Blood/BM) | Chronic Lymphocytic Leukemia | FDA-Cleared |
| clonoSEQ LDT Portfolio | Various Lymphoid Malignancies | CLIA LDT |
| TCR Therapeutics Pipeline | Cancer, Autoimmune, Infectious Disease | Discovery/Preclinical |
| Antibody Therapeutics (SARS-CoV-2) | COVID-19 | Discovery/Preclinical |
| Antibody Therapeutics Platform | Broad | Discovery/Preclinical |
Leadership Team at Adaptive Biotechnologies
CR
Chad Robins
Chief Executive Officer, Co-founder, Chairman of the Board
HR
Harlan Robins, PhD
Chief Scientific Officer & Co-founder
JR
Julie Rubinstein
President & Chief Operating Officer
SB
Sharon Benzeno, PhD
Chief Commercial Officer, Immune Medicine
FL
Francis Lo
Chief People Officer
SB
Susan Bobulsky
Chief Commercial Officer, MRD
PN
Peter Neupert
Board Member
MG
Michelle Griffin
Board Member
RH
Robert Hershberg, MD, PhD
Board Member
KO
Katey Owen, PhD
Board Member